About US
Contact us
-
J&J prevails in first talc appeal as judges vacate $72M verdictJohnson & Johnson may have incidentally scored a major victory in the Supreme Court case brought by another drugmaker, Bristol-Myers Squibb. Because of a Bristol ruling this summer, J&J has2017/10/13
-
J&J's Remicade stands firm against biosim competition in Q3Under a growing biosimilar assault, Johnson & Johnson's big-selling immunology biologic Remicade held its ground again in the third quarter. Now, executives are planning their 2018 defense strat2017/10/13
-
Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics companySurprise, surprise: Impax Labs, looking tobulk upamid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal. On Tuesday, the companysaidit had inked an all2017/10/12
-
With Kite in the bag, Gilead boosts oncology chief Riva to the head tableWhat comes after a successful M&A hunt? A promotion for the lead deal scout. Weeks after sewing up a $11.9 billion deal for Kite Pharma and its cell therapy engine, Gilead Sciencessaidit's promoti2017/10/12
-
Johnson & Johnson says Puerto Rico plants 'fared well' in Maria but 'intermittent' shortages possibleIn the wake of the devastating Hurricane Maria in Puerto Rico, Johnson & Johnson executives say the company's manufacturing facilities "fared well" and are getting back up to full speed. "Int2017/10/11
-
Generics squeeze forces Novartis Colorado plant close, imperiling 450 jobsSome drugmakers are responding to industrywide generics pricing pressure by bulking up via M&A, but not Novartis. The Swiss company's Sandoz unit plans to scale back or nix production of some g2017/10/11
-
Biotech CDMO iBio teams with Aethlon to provide recombinant GNAiBio, a CDMO that focuses on plant-based biotechnology, said it reached an agreement to support Aethlon Medical with the production of its blood purification device. Thetwo companieshave previously2017/10/10
-
Allergan loses Restasis patent protections in federal court decisionAfter stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye med Restasis. A federal judge invalidated exclusive protections for the drug—Allergan's2017/10/10
-
Lilly wards off another Alimta patent challenge, this time through IPREli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too. The Indianapolis pharma has won an IPR challen2017/10/9
-
With new bill, Sen. McCaskill looks to end 'brazen' tribal licensing strategyOnly days after Sen. Claire McCaskill reached out to drug industry leadership with concerns over Allergan's tribal licensing deal, she's moving to shut down the "brazen loophole." The influential se2017/10/9